A Randomized, Active-controlled, Parallel, Open-label, Multicenter, Phase 4 Study to Compare the Efficacy and Safety of Pregabalin Sustained Release Tablet and Pregabalin Immediate Release Capsule in Type II Diabetic Patients With Peripheral Neuropathic Pain
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 130 participants.
Also called NCT05624853
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 130 participants
- Sponsor
- Registry
-
NCT05624853
-
- Other papers using this trial's data
- A phase 4 randomized active-controlled clinical study to compare the efficacy and safety of sustained-release pregabalin with immediate-release pregabalin in type 2 diabetic patients with peripheral neuropathic pain
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT05624853. Randomized; no masking; primary purpose treatment. Start 2020-05-12 (actual); primary completion 2022-12-20 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Randomized, Active-controlled, Parallel, Open-label, Multicenter, Phase 4 Study to Compare the Efficacy and Safety of Pregabalin Sustained Release Tablet and Pregabalin Immediate Release Capsule in Type II Diabetic Patients With Peripheral Neuropathic Pain
- Condition
- Neuropathic Pain
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- pregabalin sustained release tablet
- Intervention (Drug)
- pregabalin immediate release capsule
- Lead sponsor
- Yuhan Corporation
Record details
- Record id
cardio:ct-nct05624853- Content hash
2465a481092b6cfb0cc5a4db8bac210752bbb0edee99821747fd88d998c98bde